CACNA1I Gene as Neurological Drug Target Or Biomarker (G8911)

Target Name: CACNA1I

NCBI ID: G8911

CACNA1I

CACNA1I Gene as Neurological Drug Target Or Biomarker

CACNA1I, or CACNA1I variant 1, is a gene that has been identified as a potential drug target or biomarker for the treatment of various neurological disorders. The CACNA1I gene is located on chromosome 6 and encodes for the calcitonin receptor alpha chain, which is a G protein-coupled receptor that is involved in a variety of physiological processes in the body.

Studies have shown that individuals with the CACNA1I gene have an increased risk of developing several neurological disorders, including Alzheimer's disease, Parkinson's disease, andSeizure. Additionally, individuals with certain genetic variations in the CACNA1I gene, such as the CACNA1I variant, have been shown to have reduced levels of calcitonin, which is a hormone that is involved in regulating various physiological processes in the body, including blood pressure, bone density, and inflammation.

Research has also shown that individuals with the CACNA1I variant have reduced levels of the neurotransmitter serotonin, which is involved in mood, appetite, and other physiological processes in the brain. This suggests that the CACNA1I variant may be involved in the pathophysiology of certain neurological disorders, including depression and anxiety.

Despite these findings, more research is needed to fully understand the role of the CACNA1I gene in the development and progression of neurological disorders. However, the potential implications of the CACNA1I variant as a drug target or biomarker make it an important area of research, and further studies are needed to investigate its potential clinical applications.

In conclusion, the CACNA1I gene has been identified as a potential drug target or biomarker for the treatment of various neurological disorders. Further research is needed to fully understand its role in the pathophysiology of these disorders and to determine its potential as a therapeutic target. However, the potential implications of the CACNA1I variant as a drug or biomarker make it an important area of research that should be further investigated.

Protein Name: Calcium Voltage-gated Channel Subunit Alpha1 I

Functions: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. This channel gives rise to T-type calcium currents. T-type calcium channels belong to the 'low-voltage activated (LVA)' group and are strongly blocked by nickel and mibefradil. A particularity of this type of channels is an opening at quite negative potentials, and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes. Gates in voltage ranges similar to, but higher than alpha 1G or alpha 1H (By similarity)

The "CACNA1I Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CACNA1I comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets